X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-05-06 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.89 | +320 | 1,273,024 | 0% | +$285 | ||||||
| M | 2024-05-01 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.92 | +164,897 | 1,272,723 | +15% | +$151,680 | |||||
| M | 2024-04-19 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.90 | +21,528 | 1,107,807 | +2% | +$19,421 | |||||
| M | 2024-04-09 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.88 | +3,188 | 1,086,279 | 0% | +$2,805 | |||||
| M | 2024-04-03 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.91 | +17,378 | 1,083,091 | +2% | +$15,814 | |||||
| M | 2024-03-27 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.90 | +54,574 | 2,037,426 | +3% | +$49,113 | |||||
| M | 2024-03-19 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.91 | +297 | 1,011,139 | 0% | +$270 | |||||
| M | 2024-03-11 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.92 | +16,329 | 1,010,842 | +2% | +$14,951 | |||||
2024-02-26 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.90 | +20,109 | 994,513 | +2% | +$18,098 | ||||||
| M | 2024-02-20 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.89 | +77,404 | 974,404 | +9% | +$68,665 | |||||
| M | 2024-01-12 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.98 | +19,996 | 897,000 | +2% | +$19,686 | |||||
| M | 2024-01-09 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.98 | +51,502 | 877,004 | +6% | +$50,472 | |||||
| M | 2024-01-03 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.90 | +78,502 | 825,502 | +11% | +$70,413 | |||||
2023-12-20 | FRTX | Exploration Capital, LLC | 10% | P - Purchase | $0.84 | +47,000 | 747,000 | +7% | +$39,480 | ||||||
2023-12-08 | FRTX | Fox-Collis Aaron | VP of Finance, CAO | S - Sale | $0.91 | -74 | 0 | -100% | -$67 | ||||||
| M | 2023-12-04 | FRTX | Exploration Capital Fund, LP | 10% | P - Purchase | $0.88 | +30,000 | 700,000 | +4% | +$26,362 | |||||
2023-12-04 | FRTX | Fox-Colis Aaron | VP of Finance, CAO | S - Sale | $0.85 | -36 | 74 | -33% | -$31 | ||||||
| M | 2021-07-23 | BBI | Hardy Reginald L | COB | P - Purchase | $0.67 | +200,000 | 780,465 | +34% | +$133,650 | |||||
2021-07-23 | BBI | McAvoy David R. | GC, CCO | P - Purchase | $0.67 | +18,124 | 142,859 | +15% | +$12,138 | ||||||
2021-05-17 | BBI | Sklawer Andrew D | COO, Secretary | P - Purchase | $0.80 | +15,375 | 124,625 | +14% | +$12,300 | ||||||
2021-05-17 | BBI | McAvoy David R. | GC, CCO | P - Purchase | $0.80 | +26,602 | 124,735 | +27% | +$21,282 | ||||||
| M | 2021-05-18 | BBI | Chadha Deepak | Chief Research, Dev. Officer | P - Purchase | $0.83 | +15,200 | 78,167 | +24% | +$12,589 | |||||
2021-03-15 | BBI | Brown Robert Busard | CEO | P - Purchase | $1.18 | +100,000 | 316,659 | +46% | +$117,780 | ||||||
2020-09-18 | BBI | McAvoy David R. | GC, CCO | P - Purchase | $0.83 | +22,526 | 81,883 | +38% | +$18,752 | ||||||
| DM | 2020-09-15 | BBI | Veru Dennison T | Dir | P - Purchase | $0.81 | +30,000 | 1,030,840 | +3% | +$24,175 | |||||
| D | 2020-06-22 | BBI | Sklawer Andrew D | COO, Secretary | P - Purchase | $0.00 | +13,044 | 96,250 | +16% | +$0 | |||||
| D | 2020-06-22 | BBI | McAvoy David R. | GC, CCO | P - Purchase | $0.00 | +30,435 | 59,357 | +105% | +$0 | |||||
| D | 2020-06-22 | BBI | Chadha Deepak | Chief Research, Dev. Officer | P - Purchase | $0.00 | +26,087 | 46,717 | +126% | +$0 | |||||
| D | 2020-06-22 | BBI | Brown Robert Busard | CEO | P - Purchase | $0.00 | +86,957 | 216,659 | +67% | +$0 | |||||
2019-01-10 | VICL | Armistice Capital, LLC | 10% | S - Sale | $0.88 | -2,190,500 | 4,340,000 | -34% | -$1,930,707 | ||||||
2018-06-28 | VICL | Armistice Capital, LLC | 10% | P - Purchase | $1.21 | +1,276,591 | 8,721,000 | +17% | +$1,538,981 | ||||||
| M | 2018-06-25 | VICL | Armistice Capital, LLC | 10% | P - Purchase | $1.24 | +51,805 | 6,167,818 | +1% | +$64,136 | |||||
| M | 2018-06-20 | VICL | Armistice Capital, LLC | 10% | P - Purchase | $1.26 | +18,362 | 6,064,208 | 0% | +$23,061 | |||||
| M | 2018-06-14 | VICL | Armistice Capital, LLC | 10% | P - Purchase | $1.17 | +42,845 | 6,027,484 | +1% | +$50,052 | |||||
| M | 2018-06-11 | VICL | Armistice Capital, LLC | 10% | P - Purchase | $1.16 | +670,897 | 5,941,794 | +13% | +$779,329 | |||||
2018-01-22 | VICL | Armistice Capital, LLC | 10% | P - Purchase | $1.43 | +100,000 | 4,600,000 | +2% | +$143,025 | ||||||
2017-11-10 | VICL | Merton Robert C | Dir | P - Purchase | $1.75 | +85,700 | 95,451 | +879% | +$149,975 | ||||||
2017-03-27 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $2.17 | -4,250 | 9,674 | -31% | -$9,240 | +5 | -2 | +6 | |||
2017-03-15 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $2.31 | -875 | 17,696 | -5% | -$2,021 | 0 | -3 | -4 | |||
2017-02-10 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $2.26 | -4,500 | 18,571 | -20% | -$10,160 | +3 | -4 | -1 | |||
2017-02-01 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $2.16 | -3,750 | 87,420 | -4% | -$8,088 | -1 | +10 | 0 | |||
2017-01-11 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $2.48 | -54 | 23,071 | 0% | -$134 | 0 | -3 | 0 | |||
2017-01-10 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $2.45 | -5,763 | 91,170 | -6% | -$14,114 | 0 | -4 | 0 | |||
| M | 2016-12-21 | VICL | Merton Robert C | Dir | S - Sale | $2.24 | -4,000 | 9,751 | -29% | -$8,960 | +7 | +1 | -1 | ||
| M | 2016-12-19 | VICL | Merton Robert C | Dir | S - Sale | $2.21 | -4,327 | 13,751 | -24% | -$9,583 | +3 | +9 | +1 | ||
| M | 2016-12-12 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $2.39 | -15,699 | 96,933 | -14% | -$37,588 | -1 | -7 | -4 | ||
2016-12-12 | VICL | Douglas R Gordon | Dir | S - Sale | $2.39 | -10,078 | 10,828 | -48% | -$24,109 | -1 | -7 | -4 | |||
2016-12-05 | VICL | Lyons Gary A | Dir | S - Sale | $2.30 | -7,078 | 7,828 | -47% | -$16,248 | +5 | +3 | 0 | |||
2016-10-11 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $3.05 | -54 | 23,125 | 0% | -$165 | +1 | -3 | -16 | -29 | ||
2016-07-11 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $4.46 | -54 | 23,179 | 0% | -$241 | -2 | -3 | -4 | -46 | ||
| M | 2016-06-13 | VICL | Merton Robert C | Dir | P - Purchase | $4.34 | +9,000 | 18,078 | +99% | +$39,098 | +7 | -2 | 0 | -45 | |
2016-06-09 | VICL | Samant Vijay B | Pres, CEO | P - Purchase | $4.72 | +15,700 | 112,632 | +16% | +$74,154 | +3 | +7 | +7 | -41 | ||
2016-06-06 | VICL | Douglas R Gordon | Dir | P - Purchase | $4.41 | +10,078 | 20,906 | +93% | +$44,444 | +7 | +2 | +1 | -47 | ||
2016-06-03 | VICL | Lyons Gary A | Dir | P - Purchase | $4.39 | +7,078 | 14,906 | +90% | +$31,089 | -1 | -5 | +2 | -48 | ||
2016-03-15 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $0.41 | -8,750 | 232,331 | -4% | -$3,583 | -5 | -3 | -3 | -4 | ||
| M | 2016-03-01 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $0.36 | -37,500 | 969,326 | -4% | -$13,556 | +5 | +14 | +3 | +4 | |
2016-02-19 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $0.33 | -7,500 | 139,235 | -5% | -$2,477 | +6 | +9 | +21 | +29 | ||
2016-01-25 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $0.35 | -193 | 146,735 | 0% | -$68 | -3 | -3 | -3 | +18 | ||
| M | 2016-01-11 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $0.35 | -59,737 | 1,006,826 | -6% | -$20,760 | 0 | -6 | -9 | +26 | |
2016-01-11 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $0.36 | -974 | 241,081 | 0% | -$351 | 0 | -6 | -9 | +26 | ||
2016-01-07 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $0.36 | -75,000 | 1,066,563 | -7% | -$27,090 | -8 | -6 | -11 | +22 | ||
2015-10-23 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $0.39 | -193 | 146,928 | 0% | -$75 | +5 | +11 | +18 | +5 | ||
2015-10-12 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $0.43 | -974 | 242,055 | 0% | -$415 | -3 | 0 | +3 | -3 | ||
2015-10-12 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $0.41 | -4,738 | 1,141,563 | 0% | -$1,962 | -3 | 0 | +3 | -3 | ||
2015-07-23 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $0.62 | -194 | 147,121 | 0% | -$120 | -3 | +2 | -8 | -43 | ||
2015-07-13 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $0.70 | -974 | 243,029 | 0% | -$680 | -1 | -9 | -13 | -50 | ||
2015-07-13 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $0.70 | -4,737 | 1,146,301 | 0% | -$3,310 | -1 | -9 | -13 | -50 | ||
2015-07-13 | VICL | Bilinsky Igor | SVP, Corporate Development | S - Sale | $0.70 | -1,258 | 193,798 | -1% | -$879 | -1 | -9 | -13 | -50 | ||
2015-04-23 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $1.01 | -193 | 147,315 | 0% | -$195 | -4 | -8 | -8 | -59 | ||
2015-04-13 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $0.93 | -4,738 | 1,151,038 | 0% | -$4,411 | +2 | +11 | -4 | -56 | ||
2015-04-13 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $0.93 | -974 | 244,003 | 0% | -$909 | +2 | +11 | -4 | -56 | ||
2015-04-13 | VICL | Bilinsky Igor | SVP, Corporate Development | S - Sale | $0.93 | -1,257 | 195,056 | -1% | -$1,173 | +2 | +11 | -4 | -56 | ||
2015-03-30 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $0.91 | -55,000 | 1,155,776 | -5% | -$50,149 | +1 | +3 | +1 | -51 | ||
2015-01-21 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $1.09 | -428 | 147,508 | 0% | -$467 | +1 | 0 | -2 | -38 | ||
2015-01-13 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $1.12 | -4,737 | 910,776 | -1% | -$5,312 | +8 | -3 | -6 | -35 | ||
2015-01-12 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $1.16 | -1,912 | 174,977 | -1% | -$2,210 | +8 | -3 | -6 | -35 | ||
2015-01-12 | VICL | Bilinsky Igor | SVP, Corporate Development | S - Sale | $1.16 | -1,335 | 126,313 | -1% | -$1,544 | +8 | -3 | -6 | -35 | ||
2014-10-21 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $1.18 | -428 | 87,936 | 0% | -$505 | -2 | -2 | -7 | -14 | ||
2014-10-13 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $1.13 | -4,738 | 936,513 | -1% | -$5,353 | +7 | +2 | -3 | -20 | ||
2014-10-13 | VICL | Bilinsky Igor | SVP, Corporate Development | S - Sale | $1.08 | -1,335 | 127,648 | -1% | -$1,446 | +7 | +2 | -3 | -20 | ||
2014-10-13 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $1.08 | -1,912 | 176,889 | -1% | -$2,067 | +7 | +2 | -3 | -20 | ||
2014-08-26 | VICL | Bilinsky Igor | SVP, Corporate Dev't | S - Sale | $1.25 | -12,500 | 128,983 | -9% | -$15,671 | -1 | -3 | -11 | -20 | ||
2014-08-26 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $1.25 | -12,500 | 178,801 | -7% | -$15,674 | -1 | -3 | -11 | -20 | ||
2014-08-26 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $1.25 | -12,500 | 88,364 | -12% | -$15,675 | -1 | -3 | -11 | -20 | ||
2014-07-21 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $1.29 | -428 | 100,864 | 0% | -$552 | -1 | -5 | -3 | -19 | ||
2014-07-11 | VICL | Bilinsky Igor | SVP, Corporate Dev't | S - Sale | $1.16 | -1,335 | 141,483 | -1% | -$1,554 | -1 | +9 | +8 | -7 | ||
2014-07-14 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $1.17 | -4,737 | 941,251 | -1% | -$5,544 | -1 | +9 | +8 | -7 | ||
2014-07-11 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $1.16 | -1,912 | 191,301 | -1% | -$2,225 | -1 | +9 | +8 | -7 | ||
2014-04-21 | VICL | Ramos Anthony Alan | VP, Chief Accounting Officer | S - Sale | $1.22 | -428 | 101,292 | 0% | -$522 | +5 | -5 | +2 | +1 | ||
2014-04-14 | VICL | Samant Vijay B | Pres, CEO | S - Sale | $1.16 | -4,738 | 945,988 | 0% | -$5,518 | +3 | +13 | +10 | +8 | ||
2014-04-11 | VICL | Smith Lawrence Russell | VP, Vaccine Research | S - Sale | $1.21 | -1,912 | 193,213 | -1% | -$2,305 | -3 | +4 | +4 | -7 | ||
2014-04-11 | VICL | Bilinsky Igor | SVP, Corporate Dev't | S - Sale | $1.21 | -1,150 | 142,818 | -1% | -$1,387 | -3 | +4 | +4 | -7 | ||
| D | 2014-01-10 | VICL | Samant Vijay B | Pres, CEO | P - Purchase | $1.42 | +330,000 | 950,726 | +53% | +$468,600 | +18 | +24 | +12 | -11 | |
| D | 2014-01-10 | VICL | Ramos Anthony Alan | Chief Accounting Officer | P - Purchase | $1.42 | +70,000 | 102,339 | +216% | +$99,400 | +18 | +24 | +12 | -11 | |
| D | 2014-01-10 | VICL | Smith Lawrence Russell | VP, Vaccine Research | P - Purchase | $1.42 | +90,000 | 195,125 | +86% | +$127,800 | +18 | +24 | +12 | -11 | |
| D | 2014-01-10 | VICL | Bilinsky Igor | SVP, Corporate Dev't | P - Purchase | $1.42 | +90,000 | 143,968 | +167% | +$127,800 | +18 | +24 | +12 | -11 | |
2013-11-12 | VICL | Ramos Anthony Alan | Chief Accounting Officer | S - Sale | $1.11 | -7,918 | 32,339 | -20% | -$8,789 | +5 | -1 | -5 | +11 | ||
2013-09-12 | VICL | Singer James R | 10% | S - Sale | $1.29 | -200,000 | 8,670,000 | -2% | -$257,720 | -1 | -5 | +1 | +8 | ||
2013-09-11 | VICL | Singer James R | 10% | S - Sale | $1.30 | -300,000 | 8,870,000 | -3% | -$389,820 | -1 | -5 | +1 | +8 | ||
2013-09-10 | VICL | Singer James R | 10% | S - Sale | $1.23 | -200,000 | 9,170,000 | -2% | -$245,360 | -4 | -8 | -3 | +5 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |